REG - hVIVO PLC - Notice of Trading Update

hVIVOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nRSI2591Qa&default-theme=true

RNS Number : 2591Q  hVIVO PLC  09 July 2025

hVIVO plc

("hVIVO" or the "Company")

 

Notice of Trading Update

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO)
and the world leader in human challenge clinical trials, confirms that it will
issue a trading update for the six months ended 30 June 2025 on Tuesday 22
July 2025.

 

Investor presentation

 

Yamin 'Mo' Khan, Chief Executive Officer, and Stephen Pinkerton, Chief
Financial Officer, will provide a live presentation relating to the trading
update via the Investor Meet Company platform on Tuesday 22 July 2025 at
6:00pm BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.
Shareholders should be aware that the Company may not be in a position to
provide answers to all questions, particularly in relation to forward-looking
information beyond that disclosed in the trading update.

 

Investors can sign up to Investor Meet Company for free and add to meet hVIVO
here (https://www.investormeetcompany.com/hvivo-plc-1/register-investor) .
Investors who already follow hVIVO on the Investor Meet Company platform will
automatically be invited.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson,

 Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings /                 +44 (0)7980 541 893 / +44 (0)7407 804 654/

 Lianne Applegarth                               +44 (0)7584 391 303

 

 

 

Notes to Editors

 

hVIVO plc
(https://protect.checkpoint.com/v2/___https:/hvivo.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjpjNDgxOmZkYjBmOGQ2NmIyOTcwNDJmNGJkZjFkOWVmYzI1MmE2OGEwMTdmMjMzNTQ4YWVlYTg1YjgzZjAwZmJkMzc0NGE6cDpUOk4)
(Ticker: HVO) is full-service Contract Research Organisation (CRO) and the
global leader in human challenge trials. The company delivers end-to-end
clinical development services to a diverse and expanding client base,
including seven of the world's ten largest biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB
(https://protect.checkpoint.com/v2/___https:/hlabservices.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6Njo4NDI3OjM4YzRiNDBkMjg4Mzk2M2IzMjNlYzgyYzY5OGY4NzE1ODU1NTc3MjVlODdmNzcxMjQwNDNmOWE1MzI4ZDhkYmM6cDpUOk4)
brand.

 

Through its German subsidiary, CRS
(https://protect.checkpoint.com/v2/___https:/crs-earlyphase.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjoyNmIxOmYzN2ZiOTAzYjYzMWFmMmVjNDA2OTY3NzVmODg5NmQ2NTlmZmNkMzgxMTcxNDNmYzBlMGYxMDE2NGMyNjE5NDA6cDpUOk4)
, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing
early-phase clinical trial services, including first-in-human and
proof-of-concept studies. Its second subsidiary, Venn Life Sciences
(https://protect.checkpoint.com/v2/___https:/www.vennlifesciences.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjplYTdmOjgzYmE4NThiMzYyYmNiNzg5ZmU0ZDcwZWMzZmE1YTZmZDMxODRkY2NiZWZjOWNmNjM3ODhmYTUzNmQxNjI3Mzk6cDpUOk4)
, offers Early Drug Development Consulting and Biometry services to the
biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp
(https://protect.checkpoint.com/v2/___https:/flucamp.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjplMjk5OjY1ODkxMWUxZGNkOWY1ZjQxOTc1NDM0NDUxNGFmMGI5MWQyZTc4ZmQ1MWVlZWU5ZjdkZTlhOGY0NWQ2ZDJiNGY6cDpUOk4)
. Additionally, its five clinical sites support outpatient Phase II and III
trials, ensuring a seamless and efficient pathway from discovery to late-stage
development.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSLFUAEISEIW